Last reviewed · How we verify

Penicillamine (W12-W60) — Competitive Intelligence Brief

Penicillamine (W12-W60) (Penicillamine (W12-W60)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Heavy metal chelator / immunomodulator. Area: Rare disease / Metabolic disorder.

phase 3 Heavy metal chelator / immunomodulator Copper, heavy metals (non-specific chelation); collagen cross-linking inhibition Rare disease / Metabolic disorder Small molecule Live · refreshed every 30 min

Target snapshot

Penicillamine (W12-W60) (Penicillamine (W12-W60)) — Orphalan. Penicillamine is a chelating agent that binds to heavy metals and promotes their urinary excretion, while also modulating immune responses through effects on collagen cross-linking and T-cell function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Penicillamine (W12-W60) TARGET Penicillamine (W12-W60) Orphalan phase 3 Heavy metal chelator / immunomodulator Copper, heavy metals (non-specific chelation); collagen cross-linking inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Heavy metal chelator / immunomodulator class)

  1. Orphalan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Penicillamine (W12-W60) — Competitive Intelligence Brief. https://druglandscape.com/ci/penicillamine-w12-w60. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: